Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer

Michael Gnant have been the Co-Chair of the highly successful, annual St Gallen Breast Cancer Conference in Vienna, and chaired a session about the latest advances of CDK4/6 inhibitor treatment in HR+/HER2− early breast cancer, focusing on risk of recurrence.

Highligths of SABCS 2024

Kate Lathrop, MD discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2024. The studies discussed: - (01:28) Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy - (07:15) Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer - (13:02) No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial - (19:10) A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP)

Early Breast Cancer Updates

Janice Tsang, MD discusses early breast cancer updates at San Antonio Breast Cancer Symposium 2024.

PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial

Judy E. Garber, MD, MPH presents updated results of the OlympiA study at San Antonio Breast Cancer Symposium 2024. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.

Immediate Surgery Lowers Local Recurrence in Older Breast Cancer Population

Prof. Robert Hills presents a comprehensive patient-level meta-analysis of three randomized trials demonstrated that compared with surgery deferral, immediate breast surgery significantly reduces both local progression and long-term mortality in women aged 70 years or older with operable breast cancer at San Antonio Breast Cancer Symposium 2024.

Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Sara A Hurvitz, MD, FACP on the role of endocrine-based therapy in the management of breast cancer at San Antonio Breast Cancer Symposium 2024.

Efficacy and Safety of Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy by Pace of Disease Progression on Prior Endocrine-based Therapy

Prof. Giuseppe Curigliano presents the  data of the DESTINY-Breast06 at San Antonio Breast Cancer Symposium 2024.

Risk Reduction and Early Detection: Updates on Breast Cancer Screening

Ismail Jatoi, MD, PhD, FACS discusses updates on breast cancer screening at San Antonio Breast Cancer Symposium 2024.

Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies

Monica Morrow, MD, FACS discusses omission of axillary staging in ER positive breast cancer at San Antonio Breast Cancer Symposium 2024.

Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy

Kate Lathrop, MD discusses results from the phase III EMBER-3 clinical trial presented at San Antonio Breast Cancer Symposium 2024.

The Future of Cancer Genetics Is Here - Reversion Mutations in BRCA1/2 in Response to Therapy

Katherine L. Nathanson, MD discusses reversion mutations in BRCA1/2 in response to therapy at San Antonio Breast Cancer Symposium 2024.

Breast Cancer in Young Women

Matteo Lambertini, MD, PhD discusses an educational session focus on the management of breast cancer in young women at San Antonio Breast Cancer Symposium 2024.

Palbociclib Shows Benefit in HR+ HER2+ Metastatic Breast Cancer – the PATINA Trial

Otto Metzger, MD presented late-breaking results of the phase 3 PATINA trial showing addition of CDK4/6 inhibitor palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer at San Antonio Breast Cancer Symposium 2024.

COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS

Shelley Hwang, MD, MPH discusses active monitoring instead of upfront surgery may be a viable option for patients with hormone receptor-positive, HER2-negative, low-risk DCIS, according to results presented at San Antonio Breast Cancer Symposium 2024.

Estrogen Receptor Mutations in HR+ Advanced Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions

Virginia Kaklamani, MD, DSc discusses estrogen receptor mutations in HR+ advanced breast cancer and generation practice recommendations on mutation screening to guide therapeutic decisions at San Antonio Breast Cancer Symposium 2024.

Palbociclib Plus Endocrine Therapy Beats Chemo in HR+/HER2− Metastatic Breast Cancer

Prof. Sibylle Loibl presented the findings from the phase 3 PADMA clinical trial at San Antonio Breast Cancer Symposium 2024.

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)